Characterization of neutralizing monoclonal antibodies directed against tetanus toxin fragment C

References

• Ahnert-Hilger, G., Bizzini, B., Goretzki, K., et al. 1983. Monoclonal antibodies against tetanus toxin and toxoid. Med. Microbiol. Immunol. 172:123–135
   PubMed Web of Science ®Google Scholar
• Arunachalam, B., Ghosh, S., Talwar, G., and Raghupathy, R. 1992. A single human monoclonal antibody that confers total protection from tetanus. Hybridoma 11:165–179
   PubMedGoogle Scholar
• Boyd, J., Hastings, I., Farzad, Z., et al. 1984. Experiences in the production of human monoclonal antibodies to tetanus toxoid. Dev. Bol. Standard. 57:93–98
   PubMedGoogle Scholar
• Chen, C., Fu, Z., Kim, J. P., et al. 2009. Gangliosides as high affinity receptors for tetanus neurotoxin. J. Biol. Chem. 284:26569–26577
   PubMed Web of Science ®Google Scholar
• Chin, J., Sohn, Y., Lee, S. H., et al. 2003. Production of neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell. Biologicals 31:45–53
   PubMedGoogle Scholar
• Demotz, S., Matricardi, P. M., Irle, C., et al. 1989. Processing of tetanus toxin by human antigen-presenting cells. Evidence for donor and epitope-specific processing pathways. J. Immunol. 143:3881–3886
   PubMedGoogle Scholar
• Di Tommaso, A., de Magistris, M. T., Bugnoli, M., et al. 1994. Formaldehyde treatment of proteins can constrain presentation to T-cells by limiting antigen processing. Infect. Immun. 62:1830–1834
   PubMed Web of Science ®Google Scholar
• Fitzsimmons, S. P., Clark, K. C., Wilkerson, R., and Shapiro, M. A. 2000. Inhibition of tetanus toxin fragment C binding to ganglioside GT1b by monoclonal antibodies recognizing different epitopes. Vaccine 19:114–121
   PubMed Web of Science ®Google Scholar
• Galazka, A., and Gasse, F. 1995. The present status of tetanus and tetanus vaccination. Curr. Topics Microbiol. Immunol. 195:31–53
   PubMedGoogle Scholar
• Gigliotti, F., and Insel, R. 1982. Protective human hybridoma antibody to tetanus toxin. J. Clin. Invest. 70:1306–1309
   PubMed Web of Science ®Google Scholar
• Gustafsson, B., Whitmore, E., and Tiru, M. 1993. Neutralization of tetanus toxin by human monoclonal antibodies directed against tetanus toxin fragment C. Hybridoma 12:699–708
   PubMedGoogle Scholar
• Halpern, J. L., Habig, W., Neale, E., and Stibitz, S. 1990. Cloning and expression of functional fragment C of tetanus toxin. Infect. Immun. 58:1004–1009
   PubMedGoogle Scholar
• Herreros, J., Lalli, G., Montecucco, C., and Schiavo, G. 2000a. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons. J. Neurochem. 74:1941–1950
   PubMed Web of Science ®Google Scholar
• Herreros, J., Lalli, G., and Schiavo, G. 2000b. C-terminal half of tetanus toxin fragment C is sufficient for neuronal binding and interaction with a putative protein receptor. Biochem. J. 347:199–204
   Google Scholar
• Holmgren, J., Elwing, H., Fredman, P., and Svennerholm, L. 1980. Polystyrene‐adsorbed gangliosides for investigation of the structure of the tetanus toxin receptor. Eur. J. Biochem. 106:371–379
   PubMedGoogle Scholar
• Ichimori, Y., Sasano, K., Itoh, H., et al. 1985. Establishment of hybridomas secreting human monoclonal antibodies against tetanus toxin and hepatitis B virus surface antigen. Bioch. Biophys. Res. Commun. 129:26–33
   PubMed Web of Science ®Google Scholar
• Inić-Kanada, A. B., Stojanović, M. M., Živković, I. P., et al. 2009. The monoclonal antibody 26 raised against tetanus toxoid also recognizes tetanus toxin and β2-glycoprotein I-its binding properties in vitro and potential applications. J. Serb. Chem. Soc. 74:245–257
   Google Scholar
• Kamei, M., Hashizume, S., Sugimoto, N., et al. 1990. Establishment of stable mouse/human-human hybrid cell lines producing large amounts of anti-tetanus human monoclonal antibodies with high neutralizing activity. Eur. J. Epidemiol. 6:386–397
   PubMed Web of Science ®Google Scholar
• Kazemi, T., Tahmasebi, F., Bayat A. A., et al. 2011. Characterization of novel murine mono-clonal antibodies directed against extracellular domain of human HER2 tyrosine kinase receptor. Hybridoma 30:347–353
   PubMedGoogle Scholar
• Kenimer, J. G., Habig, W. H., and Hardegree, M. C. 1983. Monoclonal antibodies as probes of tetanus toxin structure and function. Infect. Immun. 42:942–948
   PubMed Web of Science ®Google Scholar
• Kozaki, S., Kamata, Y., Watarai, S., et al. 1998. Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. Microb. Pathogen. 25:91–99
   PubMed Web of Science ®Google Scholar
• Kozbor, D., Roder, J. C., Chang, T. H., et al. 1982. Human anti-tetanus toxoid monoclonal antibody secreted by EBV-transformed human B-cells fused with murine myeloma. Hybridoma 1:323–328
   PubMed Web of Science ®Google Scholar
• Lalli, G., Herreros, J., Osborne, S. L., et al. 1999. Functional characterisation of tetanus and botulinum neurotoxins binding domains. J. Cell Sci. 112:2715–2724
   PubMed Web of Science ®Google Scholar
• Lang, A., Cryz, S., Schurch, U., et al. 1993. Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J. Immunol. 151:466–472
   PubMed Web of Science ®Google Scholar
• Larrick, J. W., Truitt, K. E., Raubitschek, A. A., et al. 1983. Characterization of human hybridomas secreting antibody to tetanus toxoid. Proc. Natl. Acad. Sci. USA 80:6376–6380
   PubMed Web of Science ®Google Scholar
• Louch, H. A., Buczko, E. S., Mary, A., et al. 2002. Identification of a binding site for ganglioside on the receptor binding domain of tetanus toxin. Biochemistry 41:13644–13652
   PubMedGoogle Scholar
• Matsuda, M., Kamei, M., Sugimoto, N., et al. 1992. Characteristics of toxin-neutralization by anti-tetanus human monoclonal antibodies directed against the three functional domains [A],[B], and [C] of the tetanus toxin molecule and a reliable method for evaluating the protective effects of monoclonal antibodies. Eur. J. Epidemiol. 8:1–8
   PubMed Web of Science ®Google Scholar
• Mayer, S., Laumer, M., Mackensen, A., et al. 2002. Analysis of the immune response against tetanus toxoid: Enumeration of specific T helper cells by the Elispot assay. Immunobiology 205:282–289
   PubMed Web of Science ®Google Scholar
• Memarian, A., Hojjat-Farsangi, M., Asgarian-Omran, H., et al. 2009. Variation in WNT genes expression in different subtypes of chronic lymphocytic leukemia. Leukemia Lymphoma 50:2061–2070
   PubMed Web of Science ®Google Scholar
• Montecucco, C., and Schiavo, G. 1994. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 13:1–8
   PubMed Web of Science ®Google Scholar
• Montecucco, C., and Schiavo, G. 1995. Structure and function of tetanus and botulinum neurotoxins. Quart. Rev. Biophys. 28:423–472
   PubMed Web of Science ®Google Scholar
• Nowakowski, A., Wang, C., Powers, D., et al. 2002. Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc. Natl. Acad. Sci. USA 99:11346–11350
   PubMed Web of Science ®Google Scholar
• Petrušić, V., Živković, I., Stojanović, M., et al. 2011. Production, characterization and applications of a tetanus toxin specific monoclonal antibody T-62. Acta Histochem. 114:480–486
   PubMed Web of Science ®Google Scholar
• Rawlings, N. D., and Barrett, A. J. 1995. Evolutionary families of metallopeptidases. Meth. Enzymol. 248:183–228
   PubMed Web of Science ®Google Scholar
• Schiavo, G., Papini, E., Genna, G., and Montecucco, C. 1990. An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin. Infect. Immun. 58:4136–4141
   PubMed Web of Science ®Google Scholar
• Schiavo, G., Rossetto, O., and Montecucco, C. 1994. Clostridial neurotoxins as tools to investigate molecular events of neurotransmitter release. Semin. Cell Biol. 5:221–229
   PubMedGoogle Scholar
• Schiavo, G. G., Benfenati, F., Poulain, B., et al. 1992. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 359:832–835
   PubMed Web of Science ®Google Scholar
• Sheppard, A. J., Cussell, D., and Hughes, M. 1984. Production and characterization of monoclonal antibodies to tetanus toxin. Infect. Immun. 43:710–714
   PubMed Web of Science ®Google Scholar
• Simpson, L. L., Lake, P., and Kozaki, S. 1990. Isolation and characterization of a novel human monoclonal antibody that neutralizes tetanus toxin. J. Pharmacol. Exp. Ther. 254:98–103
   PubMed Web of Science ®Google Scholar
• Singh, A. K., Harrison, S. H., and Schoeniger, J. S. 2000. Gangliosides as receptors for biological toxins: Development of sensitive fluoroimmunoassays using ganglioside-bearing liposomes. Anal. Chem. 72:6019–6024
   PubMed Web of Science ®Google Scholar
• Volk, W., Bizzini, B., Snyder, R., et al. 1984. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect. Immun. 45:604–609
   PubMed Web of Science ®Google Scholar
• Williamson, L. C., Bateman, K. E., Clifford, J., and Neale, E. A. 1999. Neuronal sensitivity to tetanus toxin requires gangliosides. J. Biol. Chem. 274:25173–25180
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock, H. W., Reiter, C., Trenkmann, J., et al. 1986. Protection of mice against tetanus toxin by combination of two human monoclonal antibodies recognizing distinct epitopes on the toxin molecule. Hybridoma 5:21–31
   PubMed Web of Science ®Google Scholar
• Zurawski, V. R. Jr., Haber, E., and Black, P. H. 1978. Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines. Science 199:1439–1441
   PubMedGoogle Scholar